What happened
Onconic Therapeutics updated its previously filed separate results for FY2025: revenue of US$36.1M (+259.8% year on year), operating profit of US$8.53M (from a loss a year earlier) and net income of US$10.7M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$36.1M |
|---|---|
| Revenue vs a year earlier | +259.8% |
| Operating profit | US$8.53M |
| Net income | US$10.7M |
| Period | FY2025 (separate) |
| Filed | 2026-03-06, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260306901305 → open original filing |
Versions of this filing
- 2026-02-02Original
- 2026-03-06Amendment 1
- 2026-03-06Amendment 2 (this page)
Source: DART. Information only, not investment advice.